# A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

> **NCT03814291** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 31 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** IBI302
- **DRUG:** IBI302
- **DRUG:** IBI302
- **DRUG:** IBI302
- **DRUG:** IBI302
- **DRUG:** IBI302

## Key facts

- **NCT ID:** NCT03814291
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-15
- **Primary completion:** 2020-03-05
- **Final completion:** 2020-04-10
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03814291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03814291, "A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03814291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*